(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Health Care Sector

Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

August 29th, 2016

Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29th, 2016

1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J. / CRWE PRESS RELEASE / August 29, 2016 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) lead drug fexapotide which has been . Read more

New Long-Term Data Reinforce Safety Benefits of the World's Smallest Pacemaker

August 28th, 2016

Results Featured at ESC 2016 Demonstrate Consistent, Sustained Safety and Effectiveness for the Medtronic Micra TPS DUBLIN and ROME / CRWE PRESS RELEASE / AUGUST 28, 2016 - In the largest and longest clinical evaluation of leadless pacing patients. Read more

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

August 22nd, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

August 17th, 2016

Toronto, Ontario / CRWE PRESS RELEASE / August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food . Read more

Medtronic Completes $20 Million Second Tranche Investment In Mazor Robotics

August 15th, 2016

CAESAREA, Israel / CRWE PRESS RELEASE / August 15, 2016 – Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity inv. Read more

ViewRay's MRIdian System Receives Japanese Regulatory Approval (Shonin)

August 15th, 2016

Expands MRI-Guided Radiation Therapy Access to World’s Third Largest Market CLEVELAND / CRWE PRESS RELEASE / August 15, 2016 – ViewRay, Inc. (Nasdaq: VRAY)announced today that the company received Shonin approval from the Japanese. Read more

Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program

August 09th, 2016

- The study will enroll about 250 patients in Europe and the U.S. - The grant will cover a significant portion of the study expenses - PLX-PAD was previously selected by the EMA to be developed via the Adaptive Pathways project HAIFA, ISRAE. Read more

Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study

August 03rd, 2016

Rancho Cordova, Calif. / CRWE PRESS RELEASE / August 03, 2016 - Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up results for a number of patients that particip. Read more

GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016

August 03rd, 2016

London, UK / CRWE PRESS RELEASE / Aug. 02, 2016 - GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel thera. Read more

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

August 02nd, 2016

- CLI is a severe unmet medical need whose treatment addresses a $12 billion global market - Multinational study to be conducted in U.S. and Europe - Estimated trial enrollment of approximately 250 patients - Primary endpoint for BLA will be time . Read more

Load More Content